Connect with us

News

Uterine Cancer Diagnostics Market 2019: Global Industry Trends, Growth, Size, Segmentation, Future Demands, Latest Innovation, Sales Revenue by Regional Forecast to 2026

gbafNews28

The increasing prevalence of uterine cancer worldwide is driving the global uterine cancer diagnostics testing market, says Fortune Business Insights in their new study. The study is titled,” Uterine Cancer Diagnostics Testing Market Size, Share and Global Trend by Type (Blood test, Endometrial biopsy, Imaging, Others), By End-user (Hospitals, Diagnostic centers, Cancer research centers, Others) and Geography Forecast till 2026”.

Browse Complete Report Details at https://www.fortunebusinessinsights.com/industry-reports/uterine-cancer-diagnostics-testing-market-100582

Companies operating in the Global Uterine Cancer Diagnostics Testing Market are;

  • Siemens Healthcare Private Limited
  • BD
  • Abbott
  • Hoffmann-La Roche Ltd.
  • bioMérieux
  • Danaher and others.

According to the report, the market is anticipated to be dominated by the endometrial biopsysegment on the basis of segmentation by type. This is because of the higher adoption of uterine testing diagnostics testing equipment and the cost associated with the process.

Rising Prevalence of Uterine Cancer Driving Market

The global market for uterine cancer diagnostics testing is growing because of the rising incidence of cancer of the uterus worldwide. The National Cancer Institute of the U.S. states an estimate of 60,000 new cases of uterine cancer in 2019, which, in some cases, leads to gestational trophoblastic disease, where cells inside a woman’s uterus grows abnormally. The rising prevalence of uterine cancer is a major factor boosting the global market and anticipated to continue doing the same in the coming years as well.

The Canadian Cancer Society stated in 2017 the number of women diagnosed with uterine cancer in Canada alone was 7,300. The department of Health and Human Services estimates 11.0% of women between ages 15 to 40 years suffer from endometriosis every year in the U.S. the aforementioned factors are anticipated to drive the market remarkably in the coming years. This, coupled with, the rising prevalence of diabetes and people suffering from obesity per year in the U.S., are expected to boost the global market for uterine cancer diagnostics in the near future.

On the flipside, the market may face challenges in terms of high installation costs of uterine cancer diagnostic imaging systems, and the complications related to the patient’s maternity post biopsy procedure. Additionally, the lack of skilled doctors and shortage of healthcare resources such as radiologists in developing nations may also hamper the market in the coming years.

Nevertheless, government initiatives regarding the various cancer types and improvement in treatment facilities over the time is anticipated to propel demand for uterine cancer therapeutics in the market. This, accompanied with the rising disposable income of the people is propelling people to opt for better treatment facilities.

Get Sample PDF Brochure at https://www.fotunebusinessinsights.com/enquiry/request-sample-pdf/uterine-cancer-diagnostics-testing-market-100582

Asia Pacific to Witness Faster Growth on Account of Improving Healthcare Facilities in Emerging Economies

Fortune Business Insights foresees the global uterine cancer diagnostics testing market to be dominated by North America. This is because of the increasing prevalence of uterine cancer in the region. On the other hand, the market in Asia Pacific is anticipated to grow at faster rates because of the increasing healthcare facilities in the emerging economies of India, and China. This, accompanied with the rising awareness about various types of cancer, especially of the uterine is anticipated to bring lucrative opportunities for the market in Asia Pacific and help it emerge as the fastest growing region.

View Related Report at

Immunology Market to Rise Impressively at 8.1%; Increasing Product Approvals to Favor Market Growth

Neurodegenerative Diseases Drugs Market Exhibits 7.2% CAGR, Increasing Prevalence of Neurodegenerative Diseases to Foster Growth

About Us:

Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights we aim at highlighting the most lucrative growth opportunities for our clients. We therefore offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

Contact Us

Fortune Business Insights Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune-Bangalore Highway,
Pune – 411045, Maharashtra, India.
Phone:
US: +1 424 253 0390
UK: +44 2071 939123
APAC: +91 744 740 1245
Email: [email protected].

News

SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Innate Pharma S.A. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

gbafNews28

The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Innate Pharma S.A. (Innate or the Company) (NASDAQ: IPHA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company’s securities between March 10, 2020 and September 8, 2020, inclusive (the ”Class Period”), are encouraged to contact the firm before December 22, 2020.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at [email protected].

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Innate touted the results of its Phase 2 trials as meeting their expectations. The Company continued to promise investors that its results would make it eligible for a $100 million payment upon beginning a Phase 3 trial. The Company failed to provide timely disclosure to the market regarding the renegotiation of its agreement with AstraZeneca for the $100 million payment, which would split the total amount into two $50 million payments contingent on performance. Based on these facts, the Companys public statements were false and materially misleading throughout the class period. When the market learned the truth about Innate, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

The Schall Law Firm

Brian Schall, Esq.,

www.schallfirm.com

Office: 310-301-3335

[email protected]

Continue Reading

News

SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against JPMorgan Chase & Co. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

gbafNews28

The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against JPMorgan Chase & Co. (JP Morgan or the Company) (NYSE: JPM) violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company’s securities between February 23, 2016 and September 23, 2020, inclusive (the ”Class Period”), are encouraged to contact the firm before December 23, 2020.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at [email protected].

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. JP Morgans traders, with the permission of the Companys executives, manipulated the precious metals market using fake orders to spoof the appearance of market demand. The Company failed to maintain appropriate controls to stop such misconduct. This conduct resulted in regulatory scrutiny, during which the Company misled investigators, ultimately leading to a record-breaking $920 million fine. Based on these facts, the Companys public statements were false and materially misleading throughout the class period. When the market learned the truth about JP Morgan, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

The Schall Law Firm

Brian Schall, Esq.,

www.schallfirm.com

Office: 310-301-3335

[email protected]

Continue Reading

News

JPM LOSS NOTICE: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against JPMorgan Chase & Co. – JPM

gbafNews28

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of JPMorgan Chase & Co. (NYSE: JPM) between February 23, 2016 and September 23, 2020, inclusive (the Class Period). The lawsuit seeks to recover damages for JPMorgan investors under the federal securities laws.

To join the JPMorgan class action, go to http://www.rosenlegal.com/cases-register-1959.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) traders at the Company, with the knowledge and consent of their superiors, manipulated the precious metals market by spoofing, or placing fake orders to generate the appearance of market demand; (2) the Company had insufficient controls and compliance protocols to enable it to identify and stop the misconduct; (3) the Companys earnings in the physical commodity market were, at least in part, ill-gotten; (4) such conduct would result in enhanced regulatory scrutiny; (5) the Company provided misleading information to CFTC investigators at early stages of the investigation into the misconduct; (6) resolution of the governmental investigation into the Company would result in a record-breaking $920 million fine; and (7) as a result, Defendants statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 23, 2020. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-register-1959.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTORS ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT UPON SERVING AS LEAD PLAINTIFF.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firms attorneys are ranked and recognized by numerous independent and respected sources. Rosen Law Firm has secured hundreds of millions of dollars for investors. Attorney Advertising. Prior results do not guarantee a similar outcome.

Laurence Rosen, Esq.

Phillip Kim, Esq.

The Rosen Law Firm, P.A.

275 Madison Avenue, 40th Floor

New York, NY 10016

Tel: (212) 686-1060

Toll Free: (866) 767-3653

Fax: (212) 202-3827

[email protected]

[email protected]

[email protected]

www.rosenlegal.com

Continue Reading
Editorial & Advertiser disclosureOur website provides you with information, news, press releases, Opinion and advertorials on various financial products and services. This is not to be considered as financial advice and should be considered only for information purposes. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third party websites, affiliate sales networks, and may link to our advertising partners websites. Though we are tied up with various advertising and affiliate networks, this does not affect our analysis or opinion. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you, or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish sponsored articles or links, you may consider all articles or links hosted on our site as a partner endorsed link.
gbafNews28 gbafNews28
News10 hours ago

SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Innate Pharma S.A. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Innate...

gbafNews28 gbafNews28
News10 hours ago

SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against JPMorgan Chase & Co. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against JPMorgan...

gbafNews28 gbafNews28
News13 hours ago

JPM LOSS NOTICE: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against JPMorgan Chase & Co. – JPM

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of...

gbafNews28 gbafNews28
News13 hours ago

Liam Hendriks, Devin Williams Named 2020 Relievers of the Year Presented by The Hartford

Liam Hendriks of the Oakland Athletics is the winner of the 2020 Mariano Rivera American League Reliever of the Year...

gbafNews28 gbafNews28
News13 hours ago

Forecasted Highest Winds and Driest Conditions of the Season Mean PG&E May Need to Proactively Turn Off Power for Safety to Customers Across Northern and Central California

Pacific Gas and Electric Companys (PG&E) Emergency Operations Center, Meteorology team and Wildfire Safety Operations Center are working together and...

gbafNews28 gbafNews28
News15 hours ago

Carvana Partners with 7-Time NASCAR Cup Series Champion Jimmie Johnson and Chip Ganassi Racing in INDYCAR

Leading online auto retailer Carvana (NYSE: CVNA) announced today it will be the primary partner for 7-time NASCAR Cup Series...

gbafNews28 gbafNews28
News21 hours ago

Syros Presents Initial Data from Phase 1 Clinical Trial of SY-5609, Its Selective Oral CDK7 Inhibitor, at EORTC-NCI-AACR Meeting

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced initial safety,...

gbafNews28 gbafNews28
News1 day ago

Daiya Healthcare Makes Big Waves in the Aloha State

Daiya Healthcare, the nations leading provider group in Post-Acute and Long-Term Care Medicine, expanded operations to the Aloha State and...

gbafNews28 gbafNews28
News1 day ago

Restoration Along Oregon’s John Day River at Longview Ranch

Located along Central Oregons historic Route 19 in Kimberly, Longview Ranch maintains 30,000 stunning acres of diverse landscape. Eight miles...

gbafNews28 gbafNews28
News1 day ago

Liquid Biopsy Market | COVID-19 Recovery and Growth Opportunities | Technavio

The liquid biopsy market is poised to grow by USD 4.02 billion during 2020-2024, progressing at a CAGR of almost...